Harvard Bioscience (HBIO) Gains from Investment Securities (2023)
Harvard Bioscience (HBIO) posted quarterly Gains from Investment Securities of $259000.0 for Q4 2023, up 121.44% quarter-over-quarter from -$1.2 million in Q3 2023.
Harvard Bioscience (HBIO) Gains from Investment Securities (2023) Analysis & Trends
Harvard Bioscience (HBIO) has reported Gains from Investment Securities for 1 consecutive years, with $259000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Gains from Investment Securities changed N/A year-over-year to $259000.0; the TTM figure through Dec 2023 stood at $632000.0 (changed N/A YoY), while the FY2024 annual figure was $1.6 million, up 152.06% from the prior year.
- Gains from Investment Securities climbed to $259000.0 in Q4 2023 per HBIO's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.6 million in Q2 2023 and bottomed at -$1.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 259,000.00 |
| Dec 31, 2023 | 259,000.00 |
| Sep 30, 2023 | -1.21 Mn |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 1.58 Mn |